US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.53

-0.6062-0.55%

Post-market: 110.50-0.0338-0.03%19:30 EDT

Volume:97.95K

Turnover:10.83M

Market Cap:1.00B

PE:89.56

High:111.04

Open:110.96

Low:110.01

Close:111.14

52wk High:118.00

52wk Low:85.91

Shares:9.09M

Float Shares:9.09M

Volume Ratio:0.41

T/O Rate:1.08%

Dividend:2.18

Dividend Rate:1.97%

EPS(TTM):1.23

EPS(LYR):0.7765

ROE:--

ROA:--

PB:--

PE(LYR):142.35

Loading ...

Overview Company News Filings

Swiss Pharma Giant Hit by Triple Trial Setbacks, Shares Plunge Nearly 10% in Steepest One-Day Drop Since 2020

Abbvie : Bofa Global Research Raises Price Objective to $282.00 from $276.00

THOMSON REUTERS

Merck & Co Inc : Guggenheim Raises Target Price to $170 from $146

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug

MT Newswires Live

Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition

Stocks to Watch: Amgen, Nike, Bloom Energy

Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints

Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks

Market Chatter: Novo Nordisk Halts Two More Ziltivekimab Trials

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Merck & Company (MRK)

Novartis Might Need More Deals to Deliver Growth Ambitions

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

AlzeCure Pharma to Present at Aktiedagen Event in Stockholm

Novartis's Latest Trial Setback Sinks Stock

Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell

MT Newswires Live

Novo Nordisk (0QIU) Receives a Hold from Barclays

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Benzinga Earnings

Merck KGaA (0O14) Gets a Hold from Barclays

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PPH/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPH\",,,,,undefined,":{"symbol":"PPH","market":"US","secType":"STK","nameCN":"VanEck Pharmaceutical ETF","latestPrice":110.5338,"timestamp":1789502400000,"preClose":111.14,"halted":0,"volume":97954,"hourTrading":{"tag":"盘后","latestPrice":110.5,"preClose":110.5338,"latestTime":"19:30 EDT","volume":4792,"amount":529875.20832,"timestamp":1789515006751,"change":-0.0338,"changeRate":-0.000306,"amplitude":0.01053},"delay":0,"changeRate":-0.005454381860716224,"floatShares":9088138,"shares":9088138,"eps":1.234146,"marketStatus":"Post-Mkt","change":-0.6062,"latestTime":"09-15 19:49:41 EDT","open":110.96,"high":111.04,"low":110.01,"amount":10830806.10482,"amplitude":0.009268,"askPrice":110.88,"askSize":3000,"bidPrice":110.35,"bidSize":300,"shortable":3,"etf":1,"ttmEps":1.234146,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":111.14,"sharesOutstanding":11938138,"nav":109.45391,"aum":994732232.85,"dividendRate":0.019703,"bidAskSpread":0.00034,"preHourTrading":{"tag":"盘前","latestPrice":110.97,"preClose":111.14,"latestTime":"09:29 EDT","volume":1205,"amount":133721.50823,"timestamp":1789478999999,"change":-0.17,"changeRate":-0.00153,"amplitude":0.004769},"postHourTrading":{"tag":"盘后","latestPrice":110.5,"preClose":110.5338,"latestTime":"19:30 EDT","volume":4792,"amount":529875.20832,"timestamp":1789515006751,"change":-0.0338,"changeRate":-0.000306,"amplitude":0.01053},"volumeRatio":0.413678,"impliedVol":0.2334,"impliedVolPercentile":0.8685},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPH\",,,,,undefined,":{"symbol":"PPH","floatShares":9088138,"roa":"--","roe":"--","lyrEps":0.776475,"volumeRatio":0.413678,"shares":9088138,"dividePrice":2.1779,"high":111.04,"amplitude":0.009268,"preClose":111.14,"low":110.01,"week52Low":85.9086,"pbRate":"--","week52High":118,"institutionHeld":0,"latestPrice":110.5338,"committee":-0.818182,"eps":1.234146,"divideRate":0.019703,"volume":97954,"delay":0,"ttmEps":1.234146,"open":110.96,"prevYearClose":103.17,"prevWeekClose":109.44,"prevMonthClose":113.08,"prevQuarterClose":109.35,"fiveDayClose":110.43,"twentyDayClose":111.08,"sixtyDayClose":102.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPH\",params:#limit:5,,,undefined,":[{"date":"2026-07-01","symbol":"PPH","amount":0.6248,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-01","defaultRemindTime":1782912600000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-07","payableDate":"2026-07-01","currency":"USD","dateTimestamp":1782878400000,"payDate":"2026-07-07"},{"date":"2026-04-01","symbol":"PPH","amount":0.8441,"announcedDate":"2026-03-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-01","defaultRemindTime":1775050200000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-07","payableDate":"2026-04-01","currency":"USD","dateTimestamp":1775016000000,"payDate":"2026-04-07"},{"date":"2025-12-29","symbol":"PPH","amount":0.3106,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-29","defaultRemindTime":1767018600000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-29","currency":"USD","dateTimestamp":1766984400000,"payDate":"2025-12-31"},{"date":"2025-10-01","symbol":"PPH","amount":0.3931,"announcedDate":"2025-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-01","defaultRemindTime":1759325400000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-06","payableDate":"2025-10-01","currency":"USD","dateTimestamp":1759291200000,"payDate":"2025-10-06"},{"date":"2025-07-01","symbol":"PPH","amount":0.6069,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-01","defaultRemindTime":1751376600000,"name":"VanEck Pharmaceutical ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-07","payableDate":"2025-07-01","currency":"USD","dateTimestamp":1751342400000,"payDate":"2025-07-07"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-03","recordDate":"2016-10-05","paymentDate":"2016-10-07","value":0.2148,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-04","value":0.1449,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-07","value":0.4651,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-10","value":0.304,"currency":"USD"},{"executeDate":"2017-10-02","recordDate":"2017-10-03","paymentDate":"2017-10-06","value":0.221,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPH\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1159234329","title":"Swiss Pharma Giant Hit by Triple Trial Setbacks, Shares Plunge Nearly 10% in Steepest One-Day Drop Since 2020","url":"https://stock-news.laohu8.com/highlight/detail?id=1159234329","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159234329?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:38","pubTimestamp":1788863900,"startTime":"0","endTime":"0","summary":"Shares of Swiss pharmaceutical heavyweight Novartis AG tumbled more than 9% in European trading on September 8, marking their worst single-day performance since March 2020. The selloff came after a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B2B36J28.USD","BK4585","LU0211331839.USD","LU0320765489.SGD","LU0070302665.USD","BK4578","IE00BFTCPJ56.SGD","MEDX","PPH","BK4532","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","NVS","IE00BJT1NW94.SGD","BK4007","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665210433","title":"Abbvie : Bofa Global Research Raises Price Objective to $282.00 from $276.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2665210433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665210433?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:21","pubTimestamp":1788862905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nAZN4TIY57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","IYH","LU1267930490.SGD","PPH","FTXH","LU0114720955.EUR","LU1839511570.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU2237443978.SGD","LU2468319806.SGD","LU1236620834.HKD","IXJ","PJP","LU0128525929.USD","IE00BLSP4452.SGD","GLAM","AGNG","SG9999003800.SGD","IE00BFTCPJ56.SGD","IE00BGHQF631.EUR","LU0965509101.SGD","ABBV","LU1718418525.SGD","IE00B4R5TH58.HKD","LU1093756325.SGD","LU2433249047.HKD","IE00BN8TJ469.HKD","LU2129689431.USD","LU0553294199.USD","LU0708994859.HKD","VHT","FHLC","LU0289739699.SGD","LU1929549753.HKD","LU1989771016.USD","LU0203347892.USD","IE000WAW04H5.SGD","XLV","LU0211328371.USD","LU1061106388.HKD","LU0289961442.SGD","RXL","LU0211327993.USD","LU2237443382.USD","TRUH","IE00BVYPNV92.GBP","IE0002270589.USD","JDOC","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665281321","title":"Merck & Co Inc : Guggenheim Raises Target Price to $170 from $146","url":"https://stock-news.laohu8.com/highlight/detail?id=2665281321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665281321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:15","pubTimestamp":1788862514,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN4500A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0098860793.USD","JDOC","LU1699723380.USD","LU1941712348.USD","LU2491049909.HKD","LU0106261372.USD","RXL","SG9999013999.USD","LU0689626769.HKD","BK4533","LU1571399168.USD","LU0980610538.SGD","XLV","LU0868494708.USD","LU0070302665.USD","LU0234572021.USD","LU2324357040.USD","LU0208291251.USD","BK4588","SG9999002224.SGD","LU0861579265.USD","LU1037948541.HKD","SG9999015358.SGD","BK4516","IE000M9KFDE8.USD","SG9999002232.USD","BK4534","LU0320765646.SGD","IE00BJT1NW94.SGD","FHLC","LU2125909593.SGD","FTXH","LU2023250504.SGD","LU0124676726.USD","LU0130517989.USD","LU0238689110.USD","LU1093756325.SGD","LU1057294990.SGD","LU1989771016.USD","LU2125909247.SGD","LU2089984988.USD","LU1116320737.USD","LU0432979614.USD","LU0211331839.USD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU1934455863.HKD","LU1989772840.SGD","LU1066051811.HKD","IE00BLSP4452.SGD","LU0985320562.USD","LU1291159041.SGD","SG9999015341.SGD","SGXZ57979304.SGD","LU2433249047.HKD","LU0965509101.SGD","SG9999014567.USD","LU1037948897.HKD","LU1929549753.HKD","LU0868494617.USD","BMED","LU0289739699.SGD","LU2023250843.SGD","LU2361044949.HKD","LU2106854487.HKD","IE00B1BXHZ80.USD","GDOC","LU1035773651.USD","SG9999001176.USD","LU2360032135.SGD","LU1923622614.USD","LU0965509010.AUD","LU1941712264.USD","MRK","PAWZ","LU1989772923.USD","PPH","LU1934455194.USD","LU0965508806.USD","IXJ","LU2491050071.SGD","LU2125154778.USD","SG9999001440.SGD","LU0006306889.USD","LU1032466523.USD","IE00BLSP4239.USD","LU1917777945.USD","SG9999014559.SGD","VHT","LU2361045086.USD","IE00B4R5TH58.HKD","TRUH","LU0265550359.USD","LU0320765489.SGD","LU0265550946.USD","SG9999001176.SGD","IHE","BK4007","SG9999014575.USD","LU1201861249.SGD","LU1430594728.SGD","HRTS","LU0965509283.SGD","LU0130102774.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU0477156953.USD","LU0823416689.USD","LU0122379950.USD","LU1061106388.HKD","BK4550","LU0058720904.USD","LU0203347892.USD","LU0648001328.SGD","LU1066053197.SGD","IE0009355771.USD","LU2357627491.SGD","LU0266013472.USD","IE00BSNM7G36.USD","LU2125154935.USD","IE0002141913.USD","LU2491050154.USD","BK4559","LU0203345920.USD","LU1066051225.USD","LU1983299246.USD","LU2361044865.SGD","LU1023059063.AUD","LU0859254822.USD","LU1585245621.USD","LU1066051498.USD","LU1162221912.USD","LU1934455277.USD","LU2461242641.AUD","BK4585","LU1093756168.USD","SG9999014542.SGD","LU1069347547.HKD","LU2112291526.USD","LU0942090050.USD","IE00BN8TJ469.HKD","LU1116320901.HKD","IYH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665232106","title":"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665232106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665232106?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:10","pubTimestamp":1788862214,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-royalty-pharma-rprx-and-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-royalty-pharma-rprx-and-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1929549753.HKD","IXJ","LU0128525929.USD","PJP","LU0861579265.USD","FHLC","IYH","LU0859254822.USD","LU1291159041.SGD","IE00B3PB1722.GBP","AGNG","FTXH","BK4550","LU0965509010.AUD","RXL","BK4137","HCSG","IE00BVYPNV92.GBP","MEDX","LU1551013342.USD","LU0211328371.USD","SMMT","JDOC","LU0211327993.USD","XBI","LU1037948897.HKD","ABBV","LU0553294199.USD","LU2237443549.SGD","VHT","TRUH","LU0417517546.SGD","IE0004445239.USD","LU0029874061.USD","LU2433249047.HKD","RPRX","LABU","IE000BZT7R73.USD","LU1057294990.SGD","PPH","LU1244550494.USD","LU1003077747.HKD","GLAM","IHE","XLV","LU0823416689.USD","LU0689626769.HKD","LU2347655073.USD","PBE","LU2125909247.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665832664","title":"Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2665832664","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665832664?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:12","pubTimestamp":1788858753,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Monday its phase 3 Step Young trial evaluating once-weekly semaglutide in children aged six to under 12 with obesity met its primary endpoint.The treatment produced a superior reduction in body mass index at 68 weeks compared with a placebo, the company said.The study also achieved its secondary endpoint for body mass index classification improvement, resulting in 40.4% of treated patients no longer meeting the criteria for obesity, it said.Safety results aligned with previous trials and showed no adverse effects on growth or pubertal development, Novo Nordisk said.Shares of the company were down 1.2% in Tuesday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOX","BK4599","NVOH","THNR","OZEM","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","PPH","BK4585","BK4532","BK4588","LU1093756168.USD","LU1093756325.SGD","NVO","NVOC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326663","title":"Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326663","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326663?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:12","pubTimestamp":1788858752,"startTime":"0","endTime":"0","summary":"BUZZ-Novartis India hits record high on retina drugs distribution deal, Pfizer brand acquisition** Shares of Novartis IndiaNOIN.BOjump as much as 12.9% to a record high of 1,850.95 rupees** NOIN enters into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India** Under the deal, NOIN will exclusively distribute Accentrix and Pagenax in India, marking its entry into ophthalmology, and will pay NHPL an upfront fee of 100 million rupees ** On Monday, Novartis India said that it will acquire the Minipress brand and related IP from PfizerPFE.Nfor about 12.5 billion rupees** Pfizer IndiaPFIZ.NSwill stop selling Minipress XL and receive $13.9 million from the parent; the drug is used to treat hypertension and BPH-related urinary symptoms** YTD, NOIN up ~137%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PPH","LU0208291251.USD","LU0211331839.USD","BK4585","LU0320765489.SGD","IE00BJJMRZ35.SGD","BK4007","IE00BJT1NW94.SGD","IE0009355771.USD","NVS","MEDX","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4532","BK4588","IE00B4R5TH58.HKD","BK4578","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342326","title":"Stocks to Watch: Amgen, Nike, Bloom Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342326?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858420,"startTime":"0","endTime":"0","summary":"Amgen : Shares of the biotechnology company, a major contributor to the Dow, shed more than 5% premarket after the Swiss drugmaker Novartis  said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial. Amgen and Eli Lilly  are working on rival treatments. Novartis shares tumbled 10% in Europe, while Eli Lilly shares ticked down.Bloom Energy : The fuel-cell maker is among the companies that will join the S&P 500 later this month, S&P Dow Jones Indices announced late Friday, sending its shares 4% higher premarket. Meanwhile, Nike  will be deleted from the S&P 100. Its shares edged lower premarket.Coinbase Global , Robinhood Markets , Strategy : Shares of companies tied to cryptocurrencies retreated in premarket trading as bitcoin's price slipped more than 1% to trade below $78,500.GameStop  is set to report earnings after markets close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","MSST","BK4533","CONX","BK4007","LU0208291251.USD","BK4547","HOOI","MSTZ","AMGN","IE00BJJMRZ35.SGD","GME","LU0310800379.SGD","CTEC","LU0211331839.USD","BEZ","HOOY","HOOG","MEDX","BK4112","LU1303367103.USD","IE00B2B36J28.USD","LU0444973449.USD","NVS","IE00BFXG0V08.USD","IAI","LU1861558580.USD","BK4146","FDIG","HOOX","LU0444971666.USD","BEG","COIW","CONL","BK4599","IBLC","WNTR","MTYY","LU2089984988.USD","LU1267930813.SGD","BK4561","BK4577","LU2357125470.USD","DAPP","BK4554","NKE","APED","BEX","LU2506951792.HKD","PPH","LU1061106388.HKD","ZAP","LU0289739699.SGD","MSTX","FINX","LU1861220207.SGD","IGME","BK4595","BK4588","07399","EGGY","GMEY","IE0009355771.USD","LU0310800965.SGD","LU0889566641.SGD","BE","BK4534","LU0029864427.USD","BEC","BK4182","LU0792757196.USD","LU2264538146.SGD","LU1861217088.USD","LU2249611893.SGD","LU0052756011.USD","MSTK","WATS","BK4581","LU0957808578.USD","FRNW","ICOI","IE00BJT1NW94.SGD","GMEU","BK4127","IMST","BKCH","LU1057294990.SGD","LU0070302665.USD","BK4566","BK4585","CRPT","IBBQ","SMI3.UK","BK4578","LU2098885051.SGD","LU2294711713.HKD","04332","BK4532","IE0002141913.USD","LU0868494617.USD","LU1983299246.USD","BK4076","LU0320765992.SGD","HODU","MSII","COIO","LU2242652126.USD","PJP","BK4023","IBAT","MSTY.UK","LU0122379950.USD","LU2543165471.USD","07711","ICLN","LU0823414478.USD","09399","MSTR","SMST","07799","BITQ","LU1642822529.SGD","MSTC","BK4558","09711","BK4516","LU1571399168.USD","PBE","LU1815336760.USD","BK4600","IBB","LU0889565916.HKD","BK4596","MSTY","COIX","HOYY","LU2112291526.USD","09311","COIA","COIG","LU2360107671.USD","STYL","HOOZ","BIB","LU0823411888.USD","LMI3.UK","09799","LU0786609619.USD","LU1064131342.USD","IE00BFTCPJ56.SGD","3SMI.UK","MSDD","SG9999001440.SGD","LU1267930573.SGD","HOOC","HOOD","BK4139","MSTU","LU0708994859.HKD","MSTP","TBXU","LU0320765489.SGD","LU1861559042.SGD","OWNB","COYY","MST","LU0058720904.USD","VCLN","ROBN","VTWG","LU0128525929.USD","CONY","BPAY","SMOG","HOOW","BK4541","BK4535","CONI","IE00B4R5TH58.HKD","MSOO","UPGR","HOII","3LMI.UK","LU0128525689.USD","SIMS","MSTW","BLCK","BK4539","IE0009354923.USD","BK4551","LU0823414551.USD","COII","07311","CNRG","IE00BYQQ9H92.USD","LU0109394709.USD","BBH","LU0476273544.USD","LU1267930227.SGD","GMEC","LU2468319806.SGD","LU1988902786.USD","FIAT","COIN","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665261713","title":"Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2665261713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665261713?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:03","pubTimestamp":1788858204,"startTime":"0","endTime":"0","summary":"Novartis ($NVS) stock plunged about 13% in Tuesday’s pre-market trading as the Swiss drugmaker’s experimental drug, del-desiran, for a muscle-wasti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00B4R5TH58.HKD","MEDX","BK4578","LU0070302665.USD","LU0320765489.SGD","PPH","NVS","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4588","IE00B2B36J28.USD","IE0009355771.USD","BK4532","LU0211331839.USD","BK4007","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125754221","title":"Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks","url":"https://stock-news.laohu8.com/highlight/detail?id=1125754221","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125754221?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:00","pubTimestamp":1788858037,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical heavyweight Novartis faced a turbulent trading session on Tuesday as its shares tumbled sharply following the disclosure that its experimental drug for muscular dystrophy,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BK4585","MDTX","BMED","BK4532","IE00BJT1NW94.SGD","NVS","BK4578","LU0070302665.USD","MEDX","IE00B2B36J28.USD","IE0002141913.USD","BK4007","PSYK","IE00BJJMRZ35.SGD","BK4588","IBBQ","PPH","IE00B4R5TH58.HKD","LU0208291251.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325786","title":"Market Chatter: Novo Nordisk Halts Two More Ziltivekimab Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325786?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:57","pubTimestamp":1788857878,"startTime":"0","endTime":"0","summary":"Novo Nordisk  has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study, Reuters reported Monday.The trials, which tested the drug in heart failure patients, will end early, the company told MT Newswires. It added that patients will continue through to their 3-months follow-up as already planned.Novo said its trial testing ziltivekimab in an acute setting following a heart attack will continue as planned with results expected in H1 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","NVOH","LU1093756168.USD","NVOC","THNR","NVOX","NVO","OZEM","BK4588","IE00BKVL7J92.USD","BK4599","BK4532","BK4007","BK4585","LU1093756325.SGD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332552","title":"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332552?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:30","pubTimestamp":1788856210,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Sanofi (SNYNF) and Merck & Company (MRK) with neutral ratings, indicating that the experts are neithe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU0122379950.USD","LU0124676726.USD","LU0203347892.USD","IXJ","LU0432979614.USD","IHE","LU1989772840.SGD","LU1066051498.USD","LU2468319806.SGD","SG9999002224.SGD","SG9999014575.USD","LU1941712264.USD","LU0868494708.USD","LU1699723380.USD","IE00BLSP4239.USD","SG9999002232.USD","IE00B2B36J28.USD","LU0868494617.USD","LU2360032135.SGD","LU0689626769.HKD","PAWZ","LU1057294990.SGD","IE00BLSP4452.SGD","LU1093756168.USD","BK4588","LU0320765489.SGD","LU1116320737.USD","LU0823416689.USD","LU2361044865.SGD","GDOC","LU1941712348.USD","LU1066051811.HKD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU2491050154.USD","PPH","LU0208291251.USD","LU1035773651.USD","LU2125154778.USD","LU2125909247.SGD","SNYNF","LU1037948541.HKD","FTXH","LU2112291526.USD","BK4533","LU2361045086.USD","IE00B4R5TH58.HKD","LU1032466523.USD","SG9999013999.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","IYH","LU1585245621.USD","SGXZ57979304.SGD","VHT","LU2023250843.SGD","LU2491050071.SGD","LU0006306889.USD","LU2106854487.HKD","FHLC","SG9999014567.USD","LU1291159041.SGD","LU0648001328.SGD","LU1983299246.USD","SG9999015358.SGD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","LU1934455194.USD","LU0965509010.AUD","BK4550","BK4007","LU0130517989.USD","JDOC","LU0266013472.USD","LU1989772923.USD","LU0965508806.USD","LU1989771016.USD","HRTS","LU2433249047.HKD","LU1934455863.HKD","LU1571399168.USD","LU1917777945.USD","BK4585","IE0009355771.USD","LU0265550359.USD","LU1934455277.USD","LU1066053197.SGD","SG9999014542.SGD","LU0859254822.USD","LU1430594728.SGD","LU0130102774.USD","LU1061106388.HKD","LU1201861249.SGD","LU2361044949.HKD","LU1974910355.USD","LU2357627491.SGD","BMED","LU0320765646.SGD","MRK","LU1066051225.USD","LU0942090050.USD","LU0965509101.SGD","SG9999001440.SGD","IE00B1BXHZ80.USD","IE000M9KFDE8.USD","LU0861579265.USD","LU0211331839.USD","BK4516","LU2461242641.AUD","LU1093756325.SGD","TRUH","LU2491049909.HKD","BK4534","LU0965509283.SGD","LU2324357040.USD","LU0098860793.USD","LU1923622614.USD","LU2125909593.SGD","LU1929549753.HKD","LU2125154935.USD","LU0058720904.USD","LU0106261372.USD","IE00BJJMRZ35.SGD","LU0238689110.USD","LU1116320901.HKD","SG9999015341.SGD","LU0234572021.USD","LU0070302665.USD","LU0980610538.SGD","SG9999014559.SGD","LU1069347547.HKD","LU0265550946.USD","LU0477156953.USD","LU0985320562.USD","LU1162221912.USD","SG9999001176.USD","LU2023250504.SGD","BK4559","RXL","LU2089984988.USD","IE00BBT3K403.USD","LU0203345920.USD","LU0289739699.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323400","title":"Novartis Might Need More Deals to Deliver Growth Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323400?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:17","pubTimestamp":1788855420,"startTime":"0","endTime":"0","summary":"0817 GMT - Novartis's latest clinical-trial failure suggests the company might need more dealmaking to deliver on its ambition for steady growth beyond 2030, Jefferies analysts say in a research note. The Swiss drugmaker maintained its 2025-30 sales guidance as it said its neuromuscular drug del-desiran missed the main goal in a late-stage study. However, no comment was provided on the ambition to grow by mid-single percentage digits beyond 2030, the analysts say. Even with the recent success of a new multiple-sclerosis pill, it will be challenging to get confidence on the company's growth for the 2030s without del-desiran and del-brax, two drugs Novartis acquired from Avidity Biosciences, Jefferies says. As a result, dealmaking will likely remain part of Novartis's story, the analysts add. Shares fall 10%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0070302665.USD","BK4007","LU0320765489.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4578","BK4532","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","LU0211331839.USD","MEDX","NVS","IE0002141913.USD","IE0009355771.USD","PPH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532340","title":"Why the Dow is Being Dragged Down by a Swiss Company's Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:15","pubTimestamp":1788855300,"startTime":"0","endTime":"0","summary":"Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday.Investors returning from the Labor Day break could be forgiven for wondering if their eyes were deceiving them, but","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0320765992.SGD","LU0320765489.SGD","IE0009355771.USD","IBB","LU2242652126.USD","LU0109394709.USD","LU0070302665.USD","BK4007","LU0058720904.USD","BK4532","AMGN","LU2112291526.USD","BK4139","BK4534","LU1057294990.SGD","BK4566","IE0002141913.USD","LU0889565916.HKD","IE00B2B36J28.USD","LU0868494617.USD","LU1571399168.USD","LU2089984988.USD","PJP","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","LU2468319806.SGD","BIB","LU0208291251.USD","BK4585","LU0289739699.SGD","MEDX","SG9999001440.SGD","BK4581","NVS","TBXU","BK4599","BK4578","LU0122379950.USD","LU1023059063.AUD","BK4588","IBBQ","NAMS","PPH","BK4533","PBE","LU1983299246.USD","BBH","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323952","title":"AlzeCure Pharma to Present at Aktiedagen Event in Stockholm","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323952","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323952?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:03","pubTimestamp":1788854584,"startTime":"0","endTime":"0","summary":"AlzeCure Pharma to present at Aktiedagen event in StockholmAlzeCure will present at Aktiespararna’s Aktiedagen in Stockholm on Sept. 15.CEO Martin Jnsson is scheduled to speak at 16:25 CEST at Birger ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL83QQ0r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0672654240.SGD","CURE","LU0708995401.HKD","LU2168564065.EUR","LU0786609619.USD","LU0203202063.USD","LU0096364046.USD","LU0210536198.USD","LU2089283258.USD","LU2168564149.EUR","PPH","LU2896262040.SGD","IHE","LU0109394709.USD","LU1551013425.SGD","LU0097036916.USD","LU0158827948.USD","LU0432979614.USD","LU2023250330.USD","LU2462157665.USD","VHT","SG9999018857.SGD","SGXZ31699556.SGD","LU1988902786.USD","LU2360106947.USD","TRUH","LU0289739699.SGD","LU0114720955.EUR","LU0823416689.USD","LU2468319806.SGD","FTXH","LU0385154629.USD","LU2237443465.HKD","IE00BN29S564.USD","LU1057294990.SGD","LU1868837300.USD","LLYX","XLV","AGNG","LU0203201768.USD","LU1035775433.USD","LU0640476718.USD","LU0823434583.USD","SGXZ99366536.SGD","LU0198837287.USD","IE00B4JS1V06.HKD","GB00BDT5M118.USD","LU2168564495.EUR","BK4599","LU2361044865.SGD","SG9999017495.SGD","LU2491049909.HKD","IE00BK4W5M84.HKD","ELIL","LU2462591350.SGD","LU2211815571.USD","LU2461242641.AUD","FHLC","IE00B775H168.HKD","LU0256863902.USD","IE00BKPKM429.USD","LU0345770993.USD","IE0002141913.USD","LU1093756168.USD","LU2552382215.SGD","SG9999014906.USD","LU2271345857.HKD","LU0354030438.USD","LU2028103732.USD","IXJ","LU0174119429.USD","LU0061475181.USD","LU0320765992.SGD","LU1989771016.USD","LU1267930730.SGD","LU2112291526.USD","LU0964807845.USD","HRTS","LU2491050071.SGD","TMED","LU2750360641.GBP","LU2552382132.HKD","SGXZ81514606.USD","IE00BFTCPJ56.SGD","WDNA","LU2265009873.SGD","IE00BK4W5L77.USD","LU0820561818.USD","LU2168564222.USD","LU0106261372.USD","LU0256863811.USD","LU1291159041.SGD","LU2023251221.USD","LU2111349929.HKD","LU2168563687.JPY","LU2756315318.SGD","LU1023059063.AUD","LU1712237335.SGD","SG9999015945.SGD","LU0943347566.SGD","LU0238689110.USD","LU0058720904.USD","LU2456880835.USD","LU2602419157.SGD","JDOC","LU1069344957.HKD","LU2213496289.HKD","IE00BFSS8Q28.SGD","LU2324357040.USD","LU1814569148.SGD","BK4516","BK4007","LU1551013342.USD","LU1917777945.USD","OZEM","PJP","LU1093756325.SGD","LU1868836757.USD","LU1983299246.USD","LU2357305700.SGD","SG9999014914.USD","LU0689472784.USD","LU1548497426.USD","LU2471134523.USD","IE00BJJMRX11.SGD","LU1623119135.USD","LU1061106388.HKD","LU1868836914.USD","IE0001KFT4U8.USD","SG9999018865.SGD","LU2089284900.SGD","LU0683600562.USD","LU2063271972.USD","LU0133085943.USD","LU2491050154.USD","LU2361044949.HKD","GDOC","LU2471134879.HKD","LU2108987350.USD","LU1280957306.USD","IE00B4R5TH58.HKD","LU0471298694.HKD","LU0466842654.USD","LU1323610961.USD","SG9999015978.USD","LU1868836591.USD","LU1974910355.USD","LU2237443382.USD","SG9999001176.SGD","LU0234572021.USD","LU0079474960.USD","LU0456855351.SGD","ELIS","LU2471134796.USD","IE00BJT1NW94.SGD","LU2089984988.USD","LU2237443978.SGD","LU0225283273.USD","LU2552382058.USD","MEDX","IE00BJJMRY28.SGD","LU0320765059.SGD","LU0323591593.USD","LU1232071149.USD","LU1691799644.USD","LU2417539215.USD","LU2746668461.USD","LU1804176565.USD","SG9999015952.SGD","MEDI","ILDR","IE00BJJMRZ35.SGD","LU0823434740.USD","LU1366192091.USD","LU1720051108.HKD","LU2361045086.USD","RXL","IE00BJLML261.HKD","SG9999014898.SGD","LU2237443622.USD","LU0889565916.HKD","SG9999014880.SGD","IE00BFSS7M15.SGD","LU0353189763.USD","LU1629891620.HKD","LU1127390331.HKD","LU0820561909.HKD","LU0882574139.USD","LU0787776722.HKD","LLYZ","IE00B2B36J28.USD","LU0109391861.USD","SGXZ57979304.SGD","LU1979441026.SGD","IE00B7KXQ091.USD","LLII","IE00BWXC8680.SGD","LU2023250504.SGD","BK4588","LU2264538146.SGD","LU1868837136.USD","BK4581","LU2106854487.HKD","SG9999001176.USD","LU2756315664.SGD","LU2236285917.USD","SG9999013999.USD","SG9999015986.USD","LU2087625088.SGD","LU0094547139.USD","BK4534","IE0004445015.USD","LU0158827781.USD","LU2237443549.SGD","IE0004445239.USD","LU1064131342.USD","LU2237438978.USD","LU0266013472.USD","LU2471134952.CNY","LU0316494557.USD","LU0345770308.USD","LLY","LU2237443895.HKD","MHIP","BK4533","IE00B1XK9C88.USD","IE00B1BXHZ80.USD","LU0417517546.SGD","IE00BKDWB100.SGD","SGXZ51526630.SGD","LU1145028129.USD","IE0009355771.USD","THNR","BK4585","CANC","LU0471298777.SGD","LU0820562030.AUD","LU1720051017.SGD","LU2746668974.SGD","IE0005OL40V9.USD","IYH","LU0122379950.USD","LU0882574055.USD","LU2750360997.AUD","LU0353189680.USD","LU0354030511.USD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323985","title":"Novartis's Latest Trial Setback Sinks Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323985","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323985?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:01","pubTimestamp":1788854460,"startTime":"0","endTime":"0","summary":"Novartis shares plunged after the Swiss drugmaker said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial, the latest blow to its efforts to find new growth ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B4R5TH58.HKD","LU0208291251.USD","NVS","IE00BFTCPJ56.SGD","BK4585","MEDX","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4532","LU0070302665.USD","IE00B2B36J28.USD","BK4588","IE0002141913.USD","PPH","IE0009355771.USD","LU0211331839.USD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323534","title":"Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323534","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323534?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:58","pubTimestamp":1788854332,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.The drug candidate for the genetic muscular disorder displayed signs of clinical activity for its secondary endpoints measuring muscle strength, daily living activities, and mobility during the trial, the company said.The company is analyzing the full dataset to decide future development plans while maintaining its five-year annual sales growth target of 5% to 6% through 2030, Novartis said.Shares of the company were down by more than 13% in Tuesday premarket activity.Price: 138.80, Change: -21.19, Percent Change: -13.24","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","PPH","LU0211331839.USD","IE0002141913.USD","BK4007","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4578","BK4588","BK4532","NVS","LU0208291251.USD","MEDX","IE00B4R5TH58.HKD","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665328428","title":"Novo Nordisk (0QIU) Receives a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2665328428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665328428?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:25","pubTimestamp":1788852330,"startTime":"0","endTime":"0","summary":"Barclays analyst James Gordon CFA maintained a Hold rating on Novo Nordisk today and set a price target of DKK300.00. According to TipRanks, Gordon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOC","NVOH","NVO","BK4585","IE00BKVL7J92.USD","BK4599","BK4007","BK4532","PPH","THNR","BK4588","LU0154236417.USD","LU1093756325.SGD","NVOX","IE00BZ1G4Q59.USD","LU1093756168.USD","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665402063","title":"United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2665402063","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665402063?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:11","pubTimestamp":1788851511,"startTime":"0","endTime":"0","summary":"Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/09/61650635/united-natural-foods-abm-industries-and-3-stocks-to-watch-heading-into-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","CASY","IE00BJT1NW94.SGD","PPH","FEBU","LU1267930730.SGD","UNFI","LU0109391861.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","NVS","IE00BJJMRZ35.SGD","LU0672654240.SGD","JOYT","IE0009355771.USD","LU0320765059.SGD","BK4585","LU0708995401.HKD","BK4578","BK4113","ABM","LU0320765489.SGD","IE0009354923.USD","GXDW","IE0002141913.USD","BK4102","IE00B2B36J28.USD","LU0211331839.USD","DECU","BK4120","BK4082","FXG","LU0208291251.USD","MEDX","RGLO","BK4532","VGFPF","VOTE","BK4007","LU1878469433.USD","PMDE","BK4588","CODX","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665097340","title":"Merck KGaA (0O14) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2665097340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665097340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:05","pubTimestamp":1788851124,"startTime":"0","endTime":"0","summary":"In a report released today, James Gordon CFA from Barclays maintained a Hold rating on Merck KGaA, with a price target of €150.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/merck-kgaa-0o14-gets-a-hold-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/merck-kgaa-0o14-gets-a-hold-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IHE","LU2125909247.SGD","LU2324357040.USD","LU1989772840.SGD","SG9999013999.USD","LU1057294990.SGD","BMED","IE00BLSP4239.USD","LU1066051811.HKD","IE0002141913.USD","TRUH","IYH","PPH","LU0859254822.USD","IXJ","GDOC","SG9999001176.SGD","HRTS","XLV","IE000M9KFDE8.USD","LU1974910355.USD","LU2468319806.SGD","SG9999015341.SGD","LU2357627491.SGD","LU0289739699.SGD","LU1023059063.AUD","FTXH","VHT","LU1066051225.USD","RXL","LU0965508806.USD","LU2491049909.HKD","MRK","LU0098860793.USD","LU1069347547.HKD","LU1585245621.USD","LU2491050071.SGD","PAWZ","LU0868494617.USD","LU0130102774.USD","LU1061106388.HKD","SG9999014542.SGD","CFA","SG9999014567.USD","LU2125154935.USD","JDOC","BK4534","LU0965509010.AUD","FHLC","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665034015","title":"U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2665034015","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665034015?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:01","pubTimestamp":1788850904,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Fedex Freight Holding Company, PDF Solutions, Robinhood MarketsSept 8 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500G3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSTR","GPOR","PDFS","DG","MLM","VHT","REAI","IQRA","BHVN","SNX","VRSK","IYR","FDXF","JBTM","ABNB","SYM","PATH","ABBV","MGY","HOOD","SAIA","SPCX","FDX","APH","DLTR","ODFL","SHAK","ST","SECZ","VERA","CDW","CHRW","SLG","ADBE","FDS","MTB","FHLC","EQIX","HOOI","MANH","IRM","ONTO","PSR","ARWR","SPCF","MSDD","PPH","PTON","SG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":8,"totalSize":244,"code":"91000000","status":"200"}]}}